Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma

Affiliations

• ¹ IRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Milan, Italy.
• ² Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy.
• ³ Hematology and Bone Marrow Transplant Unit, Department of Engineering for Innovative Medicine, Section of Biomedicine of Innovation, University of Verona, Verona, Italy.
• ⁴ IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy.
• ⁵ Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy.
• ⁶ Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
• ⁷ Azienda Ospedaliero-Universitaria Pisana, UO Ematologia, Pisa, Italy.
• ⁸ Hematology Unit, San Bortolo Hospital, AULSS 8 Berica, Vicenza, Italy.
• ⁹ IRCCS Humanitas Research Hospital- Humanitas Cancer Center, Biostatistic Unit, Rozzano, Milan, Italy.
• ¹⁰ IRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Rozzano, Milan, Italy. armando.santoro@humanitas.it.
• ¹¹ Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy. armando.santoro@humanitas.it.